1. Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle.
- Author
-
Cheng J, Xu L, Yu Q, Lin G, Ma X, Li M, Guan F, Liu Y, Huang X, Xie J, Chen J, Su Z, and Li Y
- Subjects
- AMP-Activated Protein Kinases metabolism, Adenosine Monophosphate pharmacology, Adenosine Triphosphate metabolism, Adenylosuccinate Synthase metabolism, Animals, Antioxidants pharmacology, Diet, Fructose, Insulin metabolism, Muscle, Skeletal, NF-E2-Related Factor 2 metabolism, Purine Nucleotides metabolism, Purine Nucleotides pharmacology, Rats, Insulin Resistance, Metabolic Syndrome metabolism, Metformin therapeutic use
- Abstract
Nutrient excess caused by excessive fructose intake can lead to insulin resistance and dyslipidemia, which further causes the development of metabolic syndrome. Metformin is a well-known AMPK activator widely used for the treatment of metabolic syndrome, while the mechanism of AMPK activation remains unclear. The present study aimed to investigate the pharmacological effects of metformin on fructose-induced insulin resistance rat, and the potential mechanism underlying AMPK activation in skeletal muscle tissue. Results indicated that metformin significantly ameliorated features of insulin resistance, including body weight, Lee's index, hyperinsulinemia, dyslipidemia, insulin intolerance and pancreatic damage. Moreover, treatment with metformin attenuated the inflammatory response in serum and enhanced the antioxidant capacity in skeletal muscle tissue. The therapeutic effects of metformin on fructose-induced insulin resistance may be related to the activation of AMPK to regulate Nrf2 pathway and mitochondrial abnormality. Additionally, metformin suppressed the expression of adenosine monophosphate deaminase 1 (AMPD1) and up-regulated the expression of adenylosuccinate synthetase (ADSS) in the purine nucleotide cycle (PNC), which facilitated the increase of AMP level and the ratio of AMP/ATP. Therefore, we proposed a novel mechanism that metformin activated AMPK via increasing AMP by regulating the expression of AMPD1 and ADSS in PNC pathway., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF